Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice

Näytä muut versiot (1)

Background: The systemic toxicity of three candidate HIV-1 vaccines plasmid pSG2.HIVconsv DNA (D), ChAdV63.HIVconsv (C) and MVA. HIVconsv (M) expressing chimeric immunogen derived from the most conserved regions of the HIV-1 proteome was evaluated in two repeat-dose studies in the male and female BA...

Bibliografiset tiedot
Päätekijät:	Ondondo, B, Brennan, C, Nicosia, A, Crome, S, Hanke, T
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	2013

Samankaltaisia teoksia

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.
Tekijä: Ondondo, B, et al.
Julkaistu: (2013)

Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
Tekijä: Hancock, G, et al.
Julkaistu: (2017)

Optimizing Delivery of the HIVconsv Immunogen in Rhesus Macaques
Tekijä: Rosario, M, et al.
Julkaistu: (2011)

Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques
Tekijä: Borthwick, N, et al.
Julkaistu: (2015)

IL-10 Receptor Blockade Enhances CD4 and CD8 T Cell Responses to a Simian Adenovirus-Vectored HIV-1 Vaccine, ChAdV63.HIVconsv
Tekijä: Clutton, G, et al.
Julkaistu: (2013)

The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial
Tekijä: Ondondo, B, et al.
Julkaistu: (2013)

Aiming for protective T-cell responses: A focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials
Tekijä: Hanke, T
Julkaistu: (2019)

HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)
Tekijä: Beatriz Mothe, et al.
Julkaistu: (2020-05-01)

HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: Safety, immunogenicity and effect on the viral reservoir (Study BCN02)
Tekijä: Mothe, B, et al.
Julkaistu: (2020)

Parallel induction of CH505 B cell ontogeny-guided neutralizing antibodies and tHIVconsvX conserved mosaic-specific T cells against HIV-1
Tekijä: Wee, E, et al.
Julkaistu: (2019)

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1
Tekijä: Edmund G. Wee, et al.
Julkaistu: (2022-06-01)

Adenovirus Transcriptome in Human Cells Infected with ChAdOx1-Vectored Candidate HIV-1 Vaccine Is Dominated by High Levels of Correctly Spliced HIVconsv1&62 Transgene RNA
Tekijä: David A. Matthews, et al.
Julkaistu: (2023-07-01)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
Tekijä: Borthwick, N, et al.
Julkaistu: (2012)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
Tekijä: Borthwick NJ, et al.
Julkaistu: (2012-09-01)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and ChAdV-63 in a phase I/IIa clinical trial
Tekijä: Hanke, T, et al.
Julkaistu: (2012)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
Tekijä: Ahmed, T, et al.
Julkaistu: (2012)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
Tekijä: Ahmed T, et al.
Julkaistu: (2012-09-01)

Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice.
Tekijä: Ondondo, B, et al.
Julkaistu: (2014)

Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice.
Tekijä: Hanke, T, et al.
Julkaistu: (2005)

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya.
Tekijä: Hanke, T, et al.
Julkaistu: (2002)

Validation of Downloadable Mobile Snore Applications by Polysomnography (PSG)
Tekijä: Shiao YH, et al.
Julkaistu: (2024-05-01)

PSG: Peer-to-Peer semantic grid framework architecture
Tekijä: Amira Soliman, et al.
Julkaistu: (2011-07-01)

Priming with Recombinant BCG Expressing HTI Enhances the Magnitude and Breadth of the T-Cell Immune Responses Elicited by MVA.HTI in BALB/c Mice
Tekijä: Narcís Saubi, et al.
Julkaistu: (2020-11-01)

Altered primary CD8+ T cell response to a modified virus Ankara(MVA)-vectored vaccine in the absence of CD4+ T cell help.
Tekijä: Estcourt, M, et al.
Julkaistu: (2005)

Narcolepsy Diagnosis With Sleep Stage Features Using PSG Recordings
Tekijä: Jiquan Wang, et al.
Julkaistu: (2023-01-01)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
Tekijä: Ashley C. Beavis, et al.
Julkaistu: (2023-07-01)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants
Tekijä: Bliss, C, et al.
Julkaistu: (2016)

pTHr.HIVA and MVA.HIVA vaccines (gag p24/p17) augment CD4+T cell responses in chronically infected HIV-1 patients on HAART
Tekijä: Ondondo, B, et al.
Julkaistu: (2005)

A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
Tekijä: De Barra, E, et al.
Julkaistu: (2014)

MVA as a vector for vaccines against HIV-1.
Tekijä: Im, E, et al.
Julkaistu: (2004)

Phase Ia clinical evaluation of the plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
Tekijä: Sheehy, S, et al.
Julkaistu: (2011)

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
Tekijä: Sheehy, S, et al.
Julkaistu: (2011)

The Accuracy Data of the Toddlers' Nutritional Status using the "PSG Balita" App
Tekijä: Hizir Sofyan, et al.
Julkaistu: (2024-01-01)

Structure and evolution of the mouse pregnancy-specific glycoprotein (<it>Psg</it>) gene locus
Tekijä: Okumura Katsuzumi, et al.
Julkaistu: (2005-01-01)

HETEROLOGOUS PRIME-BOOST VACCINATION WITH ADCH63 AND MVA EXPRESSING MSP1 CAN INDUCE PROTECTIVE EFFICACY AGAINST SPOROZOITE CHALLENGE IN VOLUNTEERS
Tekijä: Sheehy, S, et al.
Julkaistu: (2010)

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
Tekijä: Eoghan de Barra, et al.
Julkaistu: (2014-01-01)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
Tekijä: Meyer, J, et al.
Julkaistu: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
Tekijä: Meyer, J, et al.
Julkaistu: (2013)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates
Tekijä: Capone, S, et al.
Julkaistu: (2010)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates.
Tekijä: Capone, S, et al.
Julkaistu: (2010)